KAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCE
- Written by PR Newswire
![]() |
SYDNEY, June 3, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce final data from its phase II study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298).
The data is the subject of a poster presentation at the Annual Meeting...